Compositions and methods of modulating long noncoding transcripts associated with ards induced pulmonary fibrosis
AssigneeHAYA Therapeutics SA
InventorsSamir OUNZAIN, Alexandra IOURANOVA, Daniel Roman BLESSING
Life of this patent
Estimating the term…
Abstract
Provided herein are modulators of a long noncoding transcript, pharmaceutical compositions comprising the modulator, and kits comprising the modulator. Also provided herein are methods of modulating a long noncoding transcript in a subject in need thereof. Further provided here are methods of preventing, alleviating, or treating pulmonary fibrosis or inflammation induced or associated with ARDS in a subject in need thereof.
Claims52
A modulator of a long noncoding transcript, wherein expression of the long-noncoding transcript is associated with initiation, development, or prognosis of pulmonary fibrosis associated with acute respiratory distress syndrome (ARDS).
A modulator of a long noncoding transcript, wherein the long-noncoding transcript is transcribed from a genomic region located within chr3:45,806,503 to chr3:45,831,916, and wherein the long noncoding transcript is transcribed using Crick Strand of the genomic region as template.
The modulator of any one of preceding claims, wherein the long noncoding transcript comprises at least a portion of XR_001740681.1 (NCBI), locus ENSG00000288720 (Gencode/ENSEMBL), transcript ENST00000682011.1 (Gencode/ENSEMBL), transcript ENST00000684202.1 (Gencode/ENSEMBL), or transcript RP11-852E15.3 (Gencode).
The modulator of any one of the preceding claims, wherein the expression of the long noncoding transcript is elevated in a subject affected by pulmonary fibrosis associated with acute respiratory distress syndrome (ARDS).
The modulator of any one of the preceding claims, wherein the modulator modifies expression level and/or an activity of the long noncoding transcript.
The modulator of any one of the preceding claims, wherein the modulator is a nucleic acid editing or modifying moiety.
A modulator comprising an antisense oligonucleotide (ASO), wherein the ASO comprises at least 9, 10, 11, 12, 13, 14 consecutive nucleotides with no more than 1, 2, 3 mismatches from SEQ ID NO:
- 1 (5′-GGATAATGGTTGGTCA-3′).
Dependencies are inferred from the claim text.